Pelthos Therapeutics, Inc. (PTHS)
9.48
+0.18
(+1.94%)
USD |
NYAM |
Nov 06, 10:25
Pelthos Therapeutics Gross Profit Margin (Quarterly) : 68.40% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 68.40% |
| March 31, 2026 | 70.91% |
| Date | Value |
|---|---|
| December 31, 2025 | 69.23% |
| September 30, 2025 | 54.31% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Travere Therapeutics, Inc. | 96.41% |
| ACADIA Pharmaceuticals, Inc. | 89.75% |
| Alnylam Pharmaceuticals, Inc. | 75.19% |
| Anika Therapeutics, Inc. | 65.15% |
| Savara, Inc. | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -390.2% |
| Return on Assets | -79.92% |
| Return on Invested Capital | -147.2% |
| Profit Margin (Quarterly) | -150.1% |
| Operating Margin (Quarterly) | -111.0% |
| Return on Net Operating Assets | -97.05% |